Have a personal or library account? Click to login
Advances in Treatment of Wilson Disease Cover

Advances in Treatment of Wilson Disease

Tremor and Other Hyperkinetic Movements
Volume 8 (2018): Issue 0
By: Annu Aggarwal and  Mohit Bhatt  
Open Access
|Feb 2018

References

  1. 1
    WilsonSAKProgressive lenticular degeneration—a familial nervous disease associated with cirrhosis of the liverBrain191234295509doi: 10.1093/brain/34.4.295
    Back to article
  2. 2
    CumingsJNThe copper and iron content of brain and liver in the normal and in hepato-lenticular degenerationBrain1948714105doi: 10.1093/brain/71.4.41018124738
    Back to article
  3. 3
    Denny-BrownDPorterHThe effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson’s disease)N Engl J Med195124591725doi: 10.1056/NEJM19511213245240114882450
    Back to article
  4. 4
    CumingsJNThe effects of B.A.L. in hepatolenticular degenerationBrain1951741022doi: 10.1093/brain/74.1.1014830662
    Back to article
  5. 5
    Denny-BrownDPorterHThe effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson’s disease)Trans Am Neurolog Assoc1951567984
    Back to article
  6. 6
    WalsheJMCause of death in Wilson diseaseMov Disord200722221620doi: 10.1002/mds.2169317712859
    Back to article
  7. 7
    WalsheJMThe conquest of Wilson’s diseaseBrain2009132228995doi: 10.1093/brain/awp14919596747
    Back to article
  8. 8
    AggarwalABhattMUpdate on Wilson diseaseInt Rev Neurobiol201311031348doi: 10.1016/B978-0-12-410502-7.00014-424209444
    Back to article
  9. 9
    PfeiffenbergerJWeissKHStremmelWWilson disease: symptomatic liver therapyHandb Clin Neurol20171422059doi: 10.1016/B978-0-444-63625-6.00017-328433104
    Back to article
  10. 10
    LitwinTDusekPCzlonkowskaASymptomatic treatment of neurologic symptoms in Wilson diseaseHandb Clin Neurol201714221123doi: 10.1016/B978-0-444-63625-6.00018-528433105
    Back to article
  11. 11
    AhmadATorrazza-PerezESchilskyMLLiver transplantation for Wilson diseaseHandb Clin Neurol2017142193204doi: 10.1016/B978-0-444-63625-6.00016-128433103
    Back to article
  12. 12
    LankaraniKBMalek-HosseiniSANikeghbalianSDehghaniMPourhashemiMKazemiKet alFourteen years of experience of liver transplantation for Wilson’s Disease; a report on 107 Cases from Shiraz, IranPloS one201611e0167890doi: 10.1371/journal.pone.016789027930723
    Back to article
  13. 13
    GuillaudODumortierJSobeskyRDebrayDWolfPVanlemmensCet alLong term results of liver transplantation for Wilson’s disease: experience in FranceJ Hepatol20146057989doi: 10.1016/j.jhep.2013.10.02524211743
    Back to article
  14. 14
    European Association for Study of LEASL Clinical practice guidelines: Wilson’s diseaseJ Hepatol20125667185doi: 10.1016/j.jhep.2011.11.00722340672
    Back to article
  15. 15
    RobertsEASchilskyMLAmerican Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an updateHepatology2008472089111doi: 10.1002/hep.2226118506894
    Back to article
  16. 16
    WiggelinkhuizenMTilanusMEBollenCWHouwenRHSystematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson diseaseAliment Pharmacol Ther20092994758doi: 10.1111/j.1365-2036.2009.03959.x19210288
    Back to article
  17. 17
    ChenJCChuangCHWangJDWangCWCombination therapy using chelating agent and zinc for Wilson’s diseaseJ Med Biol Eng201535697708doi: 10.1007/s40846-015-0087-726692828
    Back to article
  18. 18
    BrewerGJTreatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson diseaseArch Neurol2006635217doi: 10.1001/archneur.63.4.52116606763
    Back to article
  19. 19
    WalsheJMCopper: one man’s meat is another man’s poisonProc Nutr Soc19682710712doi: 10.1079/PNS196800225697538
    Back to article
  20. 20
    FisterWPBouldingJEBakerRAThe treatment of hepatolenticular degeneration with penicillamine; with report of two casesCan Med Assoc J1958789910213489633
    Back to article
  21. 21
    RobertsEASochaPWilson disease in childrenHandb Clin Neurol201714214156doi: 10.1016/B978-0-444-63625-6.00012-428433098
    Back to article
  22. 22
    SternliebIScheinbergIHPrevention of Wilson’s disease in asymptomatic patientsN Engl J Med19682783529doi: 10.1056/NEJM1968021527807025635646
    Back to article
  23. 23
    ScheinbergIHSternliebIWilson’s disease. Major problems in internal medicinePhiladelphiaElsevier Publishing1984
    Back to article
  24. 24
    CzlonkowskaALitwinTWilson disease – currently used anticopper therapyHandb Clin Neurol201714218191doi: 10.1016/B978-0-444-63625-6.00015-X28433101
    Back to article
  25. 25
    AggarwalABhattMThe pragmatic treatment of Wilson’s diseaseMov Disord Clin Pract201411423doi: 10.1002/mdc3.12003
    Back to article
  26. 26
    PetersRAStockenLAThompsonRHBritish anti-Lewisite (BAL)Nature19451566169doi: 10.1038/156616a021006485
    Back to article
  27. 27
    VilenskyJARedmanKBritish anti-Lewisite (dimercaprol): an amazing historyAnn Emerg Med20034137883doi: 10.1067/mem.2003.7212605205
    Back to article
  28. 28
    VilenskyJARobertsonWMGilmanSDenny-Brown, Wilson’s disease, and BAL (British antilewisite [2,3-dimercaptopropanol])Neurology2002599146doi: 10.1212/WNL.59.6.91412297577
    Back to article
  29. 29
    ByrnsMCPenningTMEnvironmental toxicology: carcinogens and heavy metals12 ed.New YorkMcGraw Hill Medical2011
    Back to article
  30. 30
    GoldsteinNPRandallRVGrossJBRosevearJWMcGWTreatment of Wilson’s disease (hepatolenticular degeneration) with DL-penicillamineNeurology19621223144doi: 10.1212/WNL.12.4.23113899920
    Back to article
  31. 31
    WalsheJMPenicillamine: the treatment of first choice for patients with Wilson’s diseaseMov Disord19991454550doi: 10.1002/1531-8257(199907)14:4<545::AID-MDS1001>3.0.CO;2-U10435489
    Back to article
  32. 32
    ScheinbergIHSternliebITreatment of the neurologic manifestations of Wilson’s diseaseArch Neurol19955233940doi: 10.1001/archneur.1995.005402800190077710368
    Back to article
  33. 33
    WalsheJMMunroNAZinc-induced deterioration in Wilson’s disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper dietArch Neurol199552101doi: 10.1001/archneur.1995.00540250012003
    Back to article
  34. 34
    ChakorRTBharoteHEklareNTamboliKUnilateral rubral tremors in Wilson’s disease treated with dimercaprolAnn Ind Acad Neurol2015181156doi: 10.4103/0972-2327.144286
    Back to article
  35. 35
    WalsheJMUnithiol in Wilson’s diseaseBr Med J19852906734doi: 10.1136/bmj.290.6469.6733918711
    Back to article
  36. 36
    HoogenraadTUVan HattumJUnithiol in Wilson’s diseaseBr Med J19852901213doi: 10.1136/bmj.290.6476.1213-a3921157
    Back to article
  37. 37
    XuSQLiXFZhuHYLiuYFangFChenLClinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson’s diseaseJ Huazhong Univ Sci Technolog Med Sci2013337437doi: 10.1007/s11596-013-1190-z24142730
    Back to article
  38. 38
    WalsheJMThe story of penicillamine: a difficult birthMov Disord2003188539doi: 10.1002/mds.1045812889074
    Back to article
  39. 39
    WalsheJMPenicillamine, a new oral therapy for Wilson’s diseaseAm J Med19562148795doi: 10.1016/0002-9343(56)90066-313362281
    Back to article
  40. 40
    WalsheJMDisturbances of aminoacid metabolism following liver injury; a study by means of paper chromatographyQuart J Med19532248350513121225
    Back to article
  41. 41
    LitinRBGoldsteinNPRandallRVPowerMHDiessnerGREffect of D,L-penicillamine on the urinary excretion of copper and calcium in hepatolenticular degeneration (Wilson’s disease)Neurology1960101236doi: 10.1212/WNL.10.2.12314417516
    Back to article
  42. 42
    OsbornSBWalsheJMStudies with radioactive copper (64Cu and 67Cu) in relation to the natural history of Wilson’s diseaseLancet1967134650doi: 10.1016/S0140-6736(67)92893-04163882
    Back to article
  43. 43
    AggarwalABhattMComplete neurological recovery in Wilson disease: experience with 100 consecutive patients seen from 2005-2013Neurology201482S47.007
    Back to article
  44. 44
    BeinhardtSLeissWStattermayerAFGraziadeiIZollerHStauberRet alLong-term outcomes of patients with Wilson disease in a large Austrian cohortClin Gastroenterol Hepatol2014126839doi: 10.1016/j.cgh.2013.09.02524076416
    Back to article
  45. 45
    DurandFBernuauJGiostraEMenthaGShouvalDDegottCet alWilson’s disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamineGut20014884952doi: 10.1136/gut.48.6.84911358907
    Back to article
  46. 46
    WeissKHThurikFGotthardtDNSchaferMTeufelUWiegandFet alEfficacy and safety of oral chelators in treatment of patients with Wilson diseaseClin Gastroenterol Hepatol201311102835. e1–2doi: 10.1016/j.cgh.2013.03.01223542331
    Back to article
  47. 47
    CzlonkowskaALitwinTKarlinskiMDziezycKChabikGCzerskaMD-penicillamine versus zinc sulfate as first-line therapy for Wilson’s diseaseEur J Neurol201421599606doi: 10.1111/ene.1234824447648
    Back to article
  48. 48
    SinhaSTalyABPrashanthLKArunodayaGRSwamyHSSuccessful pregnancies and abortions in symptomatic and asymptomatic Wilson’s diseaseJ Neurol Sci20042173740doi: 10.1016/j.jns.2003.08.00714675607
    Back to article
  49. 49
    GibbsKWalsheJMPenicillamine and pyridoxine requirements in manLancet196611759doi: 10.1016/S0140-6736(66)90700-84159097
    Back to article
  50. 50
    JaffeIAAltmanKMerrymanPThe antipyridoxine effect of penicillamine in ManJ Clin Invest19644318691873doi: 10.1172/JCI10506014236210
    Back to article
  51. 51
    KalitaJKumarVChandraSKumarBMisraUKWorsening of Wilson disease following penicillamine therapyEur Neurol20147112631doi: 10.1159/00035527624356057
    Back to article
  52. 52
    LitwinTDziezycKKarlinskiMChabikGCzepielWCzlonkowskaAEarly neurological worsening in patients with Wilson’s diseaseJ Neurol Sci20153551627doi: 10.1016/j.jns.2015.06.01026071888
    Back to article
  53. 53
    BrewerGJTerryCAAisenAMHillGMWorsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapyArch Neurol1987444903doi: 10.1001/archneur.1987.005201700200163579660
    Back to article
  54. 54
    MooresAFoxSLangAHirschfieldGMWilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory settingCan J Gastroenterol2012263339doi: 10.1155/2012/12343122720274
    Back to article
  55. 55
    RanjanAKalitaJKumarVMisraUKMRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamineNeurotoxicology201549459doi: 10.1016/j.neuro.2015.05.00426004675
    Back to article
  56. 56
    SvetelMSternicNPejovicSKosticVSPenicillamine-induced lethal status dystonicus in a patient with Wilson’s diseaseMov Disord2001165689doi: 10.1002/mds.111111391761
    Back to article
  57. 57
    PrashanthLKTalyABSinhaSRavishankarSArunodayaGRVasudevMKet alPrognostic factors in patients presenting with severe neurological forms of Wilson’s diseaseQJM20059855763doi: 10.1093/qjmed/hci09516006499
    Back to article
  58. 58
    ChanCYBakerALPenicillamine hypersensitivity: successful desensitization of a patient with severe hepatic Wilson’s diseaseAm J Gastroenterol19948944238122662
    Back to article
  59. 59
    Dell’eraLBoatiENebbiaGCoronaFWilson’s disease treated with penicillamine and lupus erythematosus: related or distinct entities?Minerva Pediatr20126455722350045
    Back to article
  60. 60
    BienaimeFClerbauxGPlaisierEMougenotBRoncoPRougierJPD-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson diseaseAm J Kidney Dis2007508215doi: 10.1053/j.ajkd.2007.05.02617954295
    Back to article
  61. 61
    AdelmanHMWintersPRMahanCSWallachPMD-penicillamine-induced myasthenia gravis: diagnosis obscured by coexisting chronic obstructive pulmonary diseaseAm J Med Sci19953091913doi: 10.1097/00000441-199504000-000017900739
    Back to article
  62. 62
    EssigmanWKMultiple side effects of penicillamine therapy in one patient with rheumatoid arthritisAnn Rheum Dis198241617620doi: 10.1136/ard.41.6.6176216862
    Back to article
  63. 63
    WalsheJMGoldingDNPenicillamine-induced arthropathy in Wilson’s diseaseProc R Soc Med197770(Suppl. 3)46
    Back to article
  64. 64
    SternliebIBennettBScheinbergIHD-penicillamine induced Goodpasture’s syndrome in Wilson’s diseaseAnn Intern Med1975826736doi: 10.7326/0003-4819-82-5-6731094875
    Back to article
  65. 65
    KarpMLurieMYonisZNephrotic syndrome in the course of treatment of Wilson’s disease with DL-penicillamineArch Dis Child1966416847doi: 10.1136/adc.41.220.6845927925
    Back to article
  66. 66
    LeeYLeeSTChoHD-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson’s diseaseClin Nephrol201685296300doi: 10.5414/CN10876326784915
    Back to article
  67. 67
    SeessleJGotthardtDNSchaferMGohdesAPfeiffenbergerJFerenciPet alConcomitant immune-related events in Wilson disease: implications for monitoring chelator therapyJ Inherit Metab Dis20163912530doi: 10.1007/s10545-015-9866-026067812
    Back to article
  68. 68
    Ingen-Housz-OroSGrootenboer-MignotSOrtonneNNahonSHorvathJBernardeschiCet alEpidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by D-penicillamine in Wilson diseaseBr J Dermatol201417115746doi: 10.1111/bjd.1315324888462
    Back to article
  69. 69
    CarlesimoMNarcisiACortesiGMariEFidanzaLDe MarcoGet alAn 18-year follow-up of a case of D-penicillamine-induced elastosis perforans serpiginosaInt J Immunopathol Pharmacol2011242579doi: 10.1177/03946320110240013321496412
    Back to article
  70. 70
    AtzoriLPinnaALPauMAsteND-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literatureDermatol Online J2011173
    Back to article
  71. 71
    KhatuSSDhuratRSNayakCSPereiraRRKagneRBPenicillamine-induced elastosis perforans serpiginosa with abnormal “lumpy-bumpy” elastic fibers in lesional and non-lesional skinIndian J Dermatol Venereol Leprol201177558doi: 10.4103/0378-6323.7498221220881
    Back to article
  72. 72
    Komal KumarRNPatilSATalyABNirmalaMSinhaSArunodayaGREffect of D-penicillamine on neuromuscular junction in patients with Wilson diseaseNeurology2004639356doi: 10.1212/01.WNL.0000137021.90567.3715365158
    Back to article
  73. 73
    NeriIGurioliCRaggiMASaracinoMAMorgantiEBugamelliFet alDetection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson’s diseaseJ Eur Acad Dermatol Venereol2015293836doi: 10.1111/jdv.1235724404914
    Back to article
  74. 74
    LeggioLFerrulliAMirijelloAAbenavoliLDi GiudaDFunicielloSet alPenicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalitiesInt J Immunopathol Pharmacol20072018590doi: 10.1177/03946320070200012217346443
    Back to article
  75. 75
    IozumiKNakagawaHTamakiKPenicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatosesJ Dermatol19972445865doi: 10.1111/j.1346-8138.1997.tb02820.x9267106
    Back to article
  76. 76
    WalsheJMManagement of penicillamine nephropathy in Wilson’s disease: a new chelating agentLancet1969214012doi: 10.1016/S0140-6736(69)90940-44188283
    Back to article
  77. 77
    DixonHBGibbsKWalsheJMPreparation of triethylenetetramine dihydrochloride for the treatment of Wilson’s diseaseLancet19721853doi: 10.1016/S0140-6736(72)90845-8
    Back to article
  78. 78
    WalsheJMCopper chelation in patients with Wilson’s disease. A comparison of penicillamine and triethylene tetramine dihydrochlorideQ J Med19734244152doi: 10.1093/oxfordjournals.qjmed.a0673464728043
    Back to article
  79. 79
    PingCCHassanYAzizNAGhazaliRAwaisuADiscontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson’s diseaseJ Clin Pharm Ther2007321017doi: 10.1111/j.1365-2710.2007.00794.x17286794
    Back to article
  80. 80
    ScheinbergIHJaffeMESternliebIThe use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson’s diseaseN Engl J Med198731720913doi: 10.1056/NEJM1987072331704053600712
    Back to article
  81. 81
    WalsheJMTreatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochlorideLancet198216437doi: 10.1016/S0140-6736(82)92201-26121964
    Back to article
  82. 82
    AskariFKGreensonJDickRDJohnsonVDBrewerGJTreatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zincJ Lab Clin Med200314238590doi: 10.1016/S0022-2143(03)00157-414713890
    Back to article
  83. 83
    Santos SilvaEESarlesJButsJPSokalEMSuccessful medical treatment of severely decompensated Wilson diseaseJ Pediatr19961282857doi: 10.1016/S0022-3476(96)70412-28636833
    Back to article
  84. 84
    DahlmanTHartvigPLofholmMNordlinderHLoofLWestermarkKLong-term treatment of Wilson’s disease with triethylene tetramine dihydrochloride (trientine)Q J Med19958860916doi: 10.1093/oxfordjournals.qjmed.a069109
    Back to article
  85. 85
    MoritaJYoshinoMWatariHYoshidaIMotohiroTYamashitaFet alWilson’s disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observationsDev Pharmacol Ther19921969doi: 10.1159/0004574561307347
    Back to article
  86. 86
    SaitoHWatanabeKSaharaMMochizukiREdoKOhyamaYTriethylene-tetramine (trien) therapy for Wilson’s diseaseTohoku J Exp Med19911642935doi: 10.1620/tjem.164.291926144
    Back to article
  87. 87
    DuboisRSRodgersonDOHambidgeKMTreatment of Wilson’s disease with triethylene tetramine hydrochloride (Trientine)J Pediatr Gastroenterol Nutr199010(1)7781doi: 10.1097/00005176-199001000-000152324883
    Back to article
  88. 88
    LingamSWilsonJNazerHMowatAPNeurological abnormalities in Wilson’s disease are reversibleNeuropediatrics198718112doi: 10.1055/s-2008-10524273561699
    Back to article
  89. 89
    HaslamRHSass-KortsakAStoutWBergMTreatment of Wilson’s disease with triethylene tetramine dihydrochloride. A case reportDev Pharmacol Ther19801(5)318247438976
    Back to article
  90. 90
    ChungEJKimEGKimSJJiKHSeoJHWilson’s disease with cognitive impairment and without extrapyramidal signs: improvement of neuropsychological performance and reduction of MRI abnormalities with trientine treatmentNeurocase201622404doi: 10.1080/13554794.2015.103297725988284
    Back to article
  91. 91
    TaylorRMChenYDhawanATriethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King’s College Hospital and review of the literatureEur J Paediatr200916810618doi: 10.1007/s00431-008-0886-8
    Back to article
  92. 92
    SternliebIWilson’s disease and pregnancyHepatology2000315312doi: 10.1002/hep.51031023910655282
    Back to article
  93. 93
    YarzeJCMartinPMunozSJFriedmanLSWilson’s disease: current statusAm J Med19929264354doi: 10.1016/0002-9343(92)90783-81605146
    Back to article
  94. 94
    AlaAAliuESchilskyMLProspective pilot study of a single daily dosage of trientine for the treatment of Wilson diseaseDig Dis Sci20156014339doi: 10.1007/s10620-014-3495-625605552
    Back to article
  95. 95
    FoxANSchilskyMOnce daily trientine for maintenance therapy of Wilson diseaseAm J Gastroenterol20081034945doi: 10.1111/j.1572-0241.2007.01646_15.x18289222
    Back to article
  96. 96
    KimBChungSJShinHWTrientine-induced neurological deterioration in a patient with Wilson’s diseaseJ Clin Neurosci2013206068doi: 10.1016/j.jocn.2012.02.04123274038
    Back to article
  97. 97
    PerryARPagliucaAFitzsimonsEJMuftiGJWilliamsRAcquired sideroblastic anaemia induced by a copper-chelating agentInt J Hematol1996646972doi: 10.1016/0925-5710(96)00457-48757970
    Back to article
  98. 98
    BogaSJainDSchilskyMLTrientine induced colitis during therapy for Wilson disease: a case report and review of the literatureBMC Pharmacol Toxicol20151630doi: 10.1186/s40360-015-0031-z26589720
    Back to article
  99. 99
    EpsteinOSherlockSTriethylene tetramine dihydrochloride toxicity in primary biliary cirrhosisGastroenterology198078144256445305
    Back to article
  100. 100
    HashimAParnellNA case of trientine overdoseToxicol Int2015221589doi: 10.4103/0971-6580.17226226862278
    Back to article
  101. 101
    BickelHNealeFCHallGA clinical and biochemical study of hepatolenticular degeneration (Wilson’s disease)Q J Med1957265275813494696
    Back to article
  102. 102
    WalsheJMTetrathiomolybdate (MoS4) as an anticopper agent in manScheinbergIHWalsheJMManchesterManchester University Press1986
    Back to article
  103. 103
    BrewerGJTetrathiomolybdate anticopper therapy for Wilson’s disease inhibits angiogenesis, fibrosis and inflammationJ Cellular Mol Med200371120doi: 10.1111/j.1582-4934.2003.tb00198.x12767257
    Back to article
  104. 104
    RuppCStremmelWWeissKHNovel perspectives on Wilson disease treatmentHandb Clin Neurol201714222530doi: 10.1016/B978-0-444-63625-6.00019-728433106
    Back to article
  105. 105
    WalterGLyndonBDepression in hepatolenticular degeneration (Wilson’s disease)Aust NZ J Psychiatry1997318802doi: 10.3109/00048679709065517
    Back to article
  106. 106
    BrewerGJJohnsonVDickRDKluinKJFinkJKBrunbergJATreatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapyArch Neurol199653101725doi: 10.1001/archneur.1996.005501001030198859064
    Back to article
  107. 107
    EsmaeliBBurnstineMAMartonyiCLSugarAJohnsonVBrewerGJRegression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson’s diseaseCornea1996155828doi: 10.1097/00003226-199611000-000088899270
    Back to article
  108. 108
    BrewerGJDickRDJohnsonVWangYYuzbasiyan-GurkanVKluinKet alTreatment of Wilson’s disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patientsArch Neurol19945154554doi: 10.1001/archneur.1994.005401800230098198464
    Back to article
  109. 109
    BrewerGJDickRDYuzbasiyan-GurkinVTankanowRYoungABKluinKJInitial therapy of patients with Wilson’s disease with tetrathiomolybdateArch Neurol199148427doi: 10.1001/archneur.1991.005301300500191986725
    Back to article
  110. 110
    BrewerGJAskariFDickRBSitterlyJFinkJKCarlsonMet alTreatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientineTransl Res2009154707doi: 10.1016/j.trsl.2009.05.00219595438
    Back to article
  111. 111
    WalsheJMYeallandMChelation treatment of neurological Wilson’s diseaseQ J Med199386197204doi: 10.1093/oxfordjournals.qjmed.a0687918369040
    Back to article
  112. 112
    MediciVTrevisanCPBigottoMAD’IncaRMartinesDDal PontEet alAdverse reaction after tetrathiomolybdate treatment for Wilson’s disease: a case reportMov Disord20062120302doi: 10.1002/mds.2110916991142
    Back to article
  113. 113
    HarperPLWalsheJMReversible pancytopenia secondary to treatment with tetrathiomolybdateBr J Haematol1986648513doi: 10.1111/j.1365-2141.1986.tb02250.x3801328
    Back to article
  114. 114
    KarunajeewaHWallAMetzJGriggACytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson’s diseaseAust NZ J Med1998282156doi: 10.1111/j.1445-5994.1998.tb02975.x
    Back to article
  115. 115
    HillGMBrewerGJPrasadASHydrickCRHartmannDETreatment of Wilson’s disease with zinc. I. Oral zinc therapy regimensHepatology198775228doi: 10.1002/hep.18400703183570163
    Back to article
  116. 116
    HoogenraadTUKoevoetRde Ruyter KorverEGOral zinc sulphate as long-term treatment in Wilson’s disease (hepatolenticular degeneration)Eur Neurol19791820511doi: 10.1159/000115077477692
    Back to article
  117. 117
    HoogenraadTUVan HattumJVan den HamerCJManagement of Wilson’s disease with zinc sulphate. Experience in a series of 27 patientsJ Neurol Sci19877713746doi: 10.1016/0022-510X(87)90116-X3819764
    Back to article
  118. 118
    BrewerGJZinc acetate for the treatment of Wilson’s diseaseExpert Opin Pharmacother2001214737doi: 10.1517/14656566.2.9.147311585025
    Back to article
  119. 119
    BrewerGJYuzbasiyan-GurkanVLeeDYAppelmanHTreatment of Wilson’s disease with zinc. VI. Initial treatment studiesJ Lab Clin Med198911463382592853
    Back to article
  120. 120
    BrewerGJDickRDJohnsonVDBrunbergJAKluinKJFinkJKTreatment of Wilson’s disease with zinc: XV long-term follow-up studiesJ Lab Clin Med199813226478doi: 10.1016/S0022-2143(98)90039-79794697
    Back to article
  121. 121
    BrewerGJDickRDYuzbasiyan-GurkanVJohnsonVWangYTreatment of Wilson’s disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosisJ Lab Clin Med1994123849588201263
    Back to article
  122. 122
    SantiagoRGottrandFDebrayDBridouxLLachauxAMoraliAet alZinc Therapy for Wilson disease in children in French pediatric centersJ Pediatric Gastroenterol Nutr2015616138doi: 10.1097/MPG.0000000000000926
    Back to article
  123. 123
    MishraDKalraVSethRFailure of prophylactic zinc in Wilson diseaseIndian Paediatr2008451513
    Back to article
  124. 124
    Castilla-HigueroLRomero-GomezMSuarezECastroMAcute hepatitis after starting zinc therapy in a patient with presymptomatic Wilson’s diseaseHepatology200032877doi: 10.1053/jhep.2000.17917
    Back to article
  125. 125
    MizuochiTKimuraAShimizuNNishiuraHMatsushitaMYoshinoMZinc monotherapy from time of diagnosis for young pediatric patients with presymptomatic Wilson diseaseJ Pediatr Gastroenterol Nutr2011533657doi: 10.1097/MPG.0b013e31821d5abe21970993
    Back to article
  126. 126
    MarcelliniMDi CiommoVCalleaFDevitoRComparcolaDSartorelliMRet alTreatment of Wilson’s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up studyJ Lab Clin Med200514513943doi: 10.1016/j.lab.2005.01.00715871305
    Back to article
  127. 127
    ChangHXuAChenZZhangYTianFLiTLong-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson’s disease in childrenExp Ther Med20135112932doi: 10.3892/etm.2013.97123599735
    Back to article
  128. 128
    HoogenraadTUvan HattumJ[Treatment of Wilson’s disease]Dtsch Med Wochenschr198711294233582206
    Back to article
  129. 129
    RanucciGDi DatoFSpagnuoloMIVajroPIorioRZinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective studyOrphanet J Rare Dis2014941doi: 10.1186/1750-1172-9-4124661374
    Back to article
  130. 130
    LinnFHHouwenRHvan HattumJvan der KleijSvan ErpecumKJLong-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patientsHepatology200950144252doi: 10.1002/hep.2318219731238
    Back to article
  131. 131
    LeeVDNorthupPGBergCLResolution of decompensated cirrhosis from Wilson’s disease with zinc monotherapy: a potential therapeutic option?Clin Gastroenterol Hepatol20064106971doi: 10.1016/j.cgh.2006.04.00716793346
    Back to article
  132. 132
    CzlonkowskaAGajdaJRodoMEffects of long-term treatment in Wilson’s disease with D-penicillamine and zinc sulphateJ Neurol199624326973doi: 10.1007/BF008685258936358
    Back to article
  133. 133
    LeWittPAPenicillamine as a controversial treatment for Wilson’s diseaseMov Disord1999145556doi: 10.1002/1531-8257(199907)14:4<555::AID-MDS1003>3.0.CO;2-L10435491
    Back to article
  134. 134
    BrewerGPenicillamine should not be used as initial therapy in Wilson’s diseaseMov Disord1999145514doi: 10.1002/1531-8257(199907)14:4<551::AID-MDS1002>3.0.CO;2-S10435490
    Back to article
  135. 135
    SinhaSTalyABWithdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson’s disease: promising, safe and cheapJ Neurol Sci200826412932doi: 10.1016/j.jns.2007.08.00617765927
    Back to article
  136. 136
    WeissKHGotthardtDNKlemmDMerleUFerenci-FoersterDSchaeferMet alZinc monotherapy is not as effective as chelating agents in treatment of Wilson diseaseGastroenterology2011140118998e1doi: 10.1053/j.gastro.2010.12.03421185835
    Back to article
  137. 137
    LangCJRabas-KolominskyPEngelhardtAKobrasGKonigHJFatal deterioration of Wilson’s disease after institution of oral zinc therapyArchives of neurology19935010078doi: 10.1001/archneur.1993.00540100008005
    Back to article
  138. 138
    RodriguezBBurgueraJBerenguerMResponse to different therapeutic approaches in Wilson disease. A long-term follow up studyAnn Hepatol2012119071423109455
    Back to article
  139. 139
    BrewerGJYuzbasiyan-GurkanVJohnsonVDickRDWangYTreatment of Wilson’s disease with zinc XII: dose regimen requirementsAm J Med Sci1993305199202doi: 10.1097/00000441-199304000-000018475943
    Back to article
  140. 140
    WiernickaAJanczykWDadalskiMAvsarYSchmidtHSochaPGastrointestinal side effects in children with Wilson’s disease treated with zinc sulphateWorld J Gastroenterol201319435662doi: 10.3748/wjg.v19.i27.435623885147
    Back to article
  141. 141
    BrewerGJJohnsonVDDickRDHederaPFinkJKKluinKJTreatment of Wilson’s disease with zinc. XVII: treatment during pregnancyHepatology20003136470doi: 10.1002/hep.51031021610655259
    Back to article
  142. 142
    Yuzbasiyan-GurkanVBrewerGJAbramsGDMainBGiacherioDTreatment of Wilson’s disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson’s diseaseJ Lab Clin Med198911452062478644
    Back to article
  143. 143
    HoogenraadTUDekkerAWvan den HamerCJCopper responsive anemia, induced by oral zinc therapy in a patient with acrodermatitis enteropathicaSci Total Environ1985423743doi: 10.1016/0048-9697(85)90005-14012288
    Back to article
  144. 144
    Foubert-SamierAKazadiARouanetMVitalALaguenyATisonFet alAxonal sensory motor neuropathy in copper-deficient Wilson’s diseaseMuscle Nerve2009402946doi: 10.1002/mus.2142519609919
    Back to article
  145. 145
    DziezycKLitwinTSobanskaACzlonkowskaASymptomatic copper deficiency in three Wilson’s disease patients treated with zinc sulphateNeurol Neurochirur Polska2014482148doi: 10.1016/j.pjnns.2014.05.002
    Back to article
  146. 146
    WillisMSMonaghanSAMillerMLMcKennaRWPerkinsWDLevinsonBSet alZinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examinationAm J Clin Pathol200512312531doi: 10.1309/V6GVYW2QTYD5C5PJ15762288
    Back to article
  147. 147
    CorteseAZangagliaRLozzaAPiccoloGPacchettiCCopper deficiency in Wilson’s disease: peripheral neuropathy and myelodysplastic syndrome complicating zinc treatmentMov Disord20112613612doi: 10.1002/mds.2352021449011
    Back to article
  148. 148
    KuchinskasEJRosenYMetal chelates of DL-penicillamineArch Biochem Biophys1962973702doi: 10.1016/0003-9861(62)90090-514460165
    Back to article
  149. 149
    AggarwalABhattMImportance of adequate decoppering in Wilson’s diseaseMov Disord2014291089doi: 10.1002/mds.25900
    Back to article
  150. 150
    WalsheJMWilson’s diseaseLancet2007369902doi: 10.1016/S0140-6736(07)60438-3
    Back to article
  151. 151
    CzlonkowskaATarnackaBLitwinTGajdaJRodoMWilson’s disease-cause of mortality in 164 patients during 1992-2003 observation periodJ Neurol2005252698703doi: 10.1007/s00415-005-0720-415742108
    Back to article
  152. 152
    MaselbasWChabikGCzlonkowskaAPersistence with treatment in patients with Wilson diseaseNeurolog Neurochirur Polska2010442603doi: 10.1016/S0028-3843(14)60040-2
    Back to article
  153. 153
    DziezycKKarlinskiMLitwinTCzlonkowskaACompliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patientsEur J Neurol2014213327doi: 10.1111/ene.1232024313946
    Back to article
  154. 154
    AggarwalAAggarwalNNagralAJankhariaGBhattMA novel Global Assessment Scale for Wilson’s Disease (GAS for WD)Mov Disord20092450918doi: 10.1002/mds.2223119115420
    Back to article
  155. 155
    VolpertHMPfeiffenbergerJGronerJBStremmelWGotthardtDNSchaferMet alComparative assessment of clinical rating scales in Wilson’s diseaseBMC Neurol201717140doi: 10.1186/s12883-017-0921-328732478
    Back to article
  156. 156
    LeinweberBMollerJCScheragAReunerUGuntherPLangCJet alEvaluation of the Unified Wilson’s Disease Rating Scale (UWDRS) in German patients with treated Wilson’s diseaseMov Disord2008235462doi: 10.1002/mds.2176117960799
    Back to article
  157. 157
    GomesADedoussisGVGeographic distribution of ATP7B mutations in Wilson diseaseAnn Human Biol20164318doi: 10.3109/03014460.2015.105149226207595
    Back to article
  158. 158
    AggarwalAChandhokGTodorovTParekhSTilveSZibertAet alWilson disease mutation pattern with genotype-phenotype correlations from Western India: confirmation of p.C271* as a common Indian mutation and identification of 14 novel mutationsAnn Hum Genet201377299307doi: 10.1111/ahg.1202423551039
    Back to article
  159. 159
    ChandhokGHorvathJAggarwalABhattMZibertASchmidtHHFunctional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell linesWorld J Gastroenterol201622410919doi: 10.3748/wjg.v22.i16.410927122662
    Back to article
  160. 160
    ChandhokGSchmittNSauerVAggarwalABhattMSchmidtHHThe effect of zinc and D-penicillamine in a stable human hepatoma ATP7B knockout cell linePloS One20149e98809doi: 10.1371/journal.pone.009880924892424
    Back to article
DOI: https://doi.org/10.5334/tohm.435 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Oct 25, 2017
Accepted on: Feb 1, 2018
Published on: Feb 28, 2018
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Wilson disease,
dimercaprol,
penicillamine,
trientine,
zinc,
tetrathiomolybdate

© 2018 Annu Aggarwal, Mohit Bhatt, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.

Previous articleVolume 8 (2018): Issue 0Next article